----

| Nevada                                                         |   | 88-0425691                           |
|----------------------------------------------------------------|--------|--------------------------------------|
| (State or other jurisdiction of incorporation or organization) |   | (I.R.S. Employer Identification No.) |
|  555 Wireless Boulevard, Hauppauge, NY |   | 11788      |
|---------------------------------------------|--------|------------|
| (Address of principal executive offices)    |   | (Zip Code) |
| Title of each class           |   | Trading symbol |   | Name of each exchange on which registered |
|-------------------------------|--------|----------------|--------|-------------------------------------------|
| Common Stock, $0.01 par value |   | CEMI           |   | The NASDAQ Stock Market LLC               |
| Large accelerated filer | ☐ | Accelerated filer         | ☒ |
|-------------------------|---------|---------------------------|---------|
| Non-accelerated filer   | ☐ | Smaller reporting company | ☒ |
|                    |    | Emerging growth company   | ☐ |

----

----

----

|       |                                                                                           | Page |
|------------|------------------------------------------------------------------------------------------------|------|
| PART III   |                                                                                           |
| Item 12.   | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 5    |
| PART IV    |                                                                                           |
| Item 15.   | Exhibits, Financial Statement Schedules                                                        | 8    |
| Signatures | 10                                                                                             |

----

Table of Contents

----

Table of Contents

| ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS |
|----------|------------------------------------------------------------------------------------------------|
|  | • | each person known to us to be the beneficial owner of more than five percent of the then-outstanding shares of common stock; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------|
|  | • | each named executive officer included in “Executive Compensation—Summary Compensation Table,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as amended; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | each current director and each nominee for election as a director; and |
|--|---------|------------------------------------------------------------------------|

|  | • | all of our executive officers, directors and director nominees as a group. |
|--|---------|----------------------------------------------------------------------------|

|                                                                               |   | Common Stock Beneficially Owned |      |
|------------------------------------------------------------------------------------|--------|---------------------------------|-----------|
| Beneficial Owner                                                                   |   | Shares                          |      |   | % |   |
| 5% Stockholders                                                                    |   |                            |      |   |   |   |
| Norman H. Pessin(1)500 Fifth Avenue, Suite 2240New York, NY 10010                  |   |                            | 1,367,587 |   |   |   | 7.8 | % |
| Nantahala Capital Management, LLC(2)130 Main Street, 2nd FloorNew Canaan, CT 06840 |   |                            | 1,239,983 |   |   |   | 7.1 | % |
| Laurence W. Lytton(3)467 Central Park WestNew York, New NY 10025                   |   |                            | 1,010,718 |   |   |   | 5.8 | % |
| Royce & Associates, LP(4)745 Fifth AvenueNew York, NY 10151                    |   |                            | 991,492   |   |   |   | 5.6 | % |
| Named Executive Officers and Directors                                             |   |                            |      |   |   |   |   |   |
| Neil A. Goldman(5)                                                                 |   |                            | 129,236   |   |   |   | * |   |
| Javan Esfandiari(6)                                                                |   |                            | 128,773   |   |   |   | * |   |
| Gail S. Page(7)                                                                    |   |                            | 88,815    |   |   |   | * |   |
| Katherine L. Davis                                                                 |   |                            | 90,143    |   |   |   | * |   |
| John G. Potthoff(8)                                                                |   |                            | 65,897    |   |   |   | * |   |
| Mary Lake Polan(9)                                                                 |   |                            | 26,522    |   |   |   | * |   |
| John J. Sperzel III(10)91 Hartwell AvenueLexington, MA 02421                       |   |                            | 31,815    |   |   |   | * |   |
| Richard L. Eberly                                                                  |   |                            | 0         |   |   |   | * |   |
| All executive officers and directors as a group (8 persons)(11)                    |   |                            | 587,293   |   |   |   | 3.3 | % |

----

Table of Contents

|   | * | Less than 1%. |
|--------|---|---------------|

|   | (1) | Based on an amended Schedule 13D filed on July 18, 2019. |
|--------|-----|----------------------------------------------------------|
|   | (2) | Based on a Schedule 13G filed on February 14, 2020. As of December 31, 2019, Nantahala may be deemed to be the beneficial owner of 1,239,983 shares held by funds and separately managed accounts under its control,                and as the managing members of Nantahala, each of Messrs. Wilmot B. Harkey and Daniel Mack may be deemed to be a beneficial owner of those shares. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | (3) | Based on a Schedule 13G filed on March 20, 2020. Of the shares, 273,264 are held for the benefit of the Lytton-Kambara Foundation, 120,048 shares  for the benefit of the  AWL Family LLC, 21,000 for the benefit of                the IKL  Trust, 13,200 for the benefit of the WWL Trust, 9,100 for the benefit of the KLL Trust, and 45,290 shares for the benefit of other accounts of  which the reporting person is deemed to have beneficial ownership. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | (4) | Based on a Schedule 13G filed on January 21, 2020. |
|--------|-----|----------------------------------------------------|
|   | (5) | Include (a) 20,725 restricted shares, one-half of which will vest on each of October 8, 2020 and 2021, and (b) options to acquire 41,666 shares. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------|
|   | (6) | Include (a) 25,907 restricted shares, one-half of which will vest on each of October 8, 2020 and 2021, and (b) options to acquire 20,000 shares. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------|
|   | (7) | Include (a) 30,864 restricted stock units scheduled to vest in full on May 15, 2020, and (b) options to acquire 28,125 shares. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------|
|   | (8) | Include options to acquire 28,125 shares. |
|--------|-----|-------------------------------------------|
|   | (9) | Include options to acquire 18,750 shares. |
|--------|-----|-------------------------------------------|
|   | (10) | Does not include shares of common stock underlying certain options that were received by Mr. Sperzel during his time as our Chief Executive Officer and President and that had vested as of the time of his                resignation. The compensation committee of the board has determined that Mr. Sperzel failed to exercise such options in a timely manner prior to their expiration. Mr. Sperzel has asserted that he continues to have the right to exercise                those options to acquire 266,666 shares for an aggregate exercise price of $943,126. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | (11) | Include, in addition to the restricted shares and options described in notes (5) through (10), (a) 6,098 restricted stock units and (b) options to acquire 36,000 shares. Do not include any shares held by Mr.                Sperzel. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| PlanCategory                                           |   | Number ofSecuritiesto be IssuedUponExercise ofOutstandingOptions,Warrants andRights |    |   | WeightedAverageExercise PriceofOutstandingOptions,Warrants |   |    | Number ofSecuritiesto be IssuedUponExercise ofOutstandingRestricted StockUnits |   |   | WeightedAverageExercise Price ofOutstandingOptions,Warrants andRights |   |   | Number of SecuritiesRemaining AvailableforFuture IssuanceUnderEquity CompensationPlans |    |
|--------------------------------------------------------|--------|-------------------------------------------------------------------------------------|---------|--------|------------------------------------------------------------|--------|---------|--------------------------------------------------------------------------------|--------|--------|-----------------------------------------------------------------------|--------|--------|----------------------------------------------------------------------------------------|---------|
| Equity compensation plans approved by stockholders(1)  |   |                                                                                | 642,625 |   |                                                       | $      | 5.79    |                                                                           |   |   | 13,817                                                                |   |   | $                                                                                      | 9.65    |   |   |   | 2,173,667 |   |
| Equity compensation plans not approved by stockholders |   |                                                                                | — |   |                                                       |   | — |                                                                           |   |   | —                                                               |   |   |                                                                                   | — |   |   |   | — |   |
| Totals                                                 |   |                                                                                | 642,625 |   |                                                       |   |    |                                                                           |   |   | 13,817                                                                |   |   |                                                                                   |    |   |   |   | 2,173,667 |   |

----

Table of Contents

|   | (1) | “Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights” consists of 99,132 shares under the 2008 Stock Incentive Plan, 336,625 shares under the 2014 Stock Incentive Plan, and                206,868 shares issued outside of those plans. “Number of Securities to be Issued Upon Exercise of Outstanding Restricted Stock” consists of 13,817 shares under the 2014 Stock Incentive Plan. “Number of Securities Remaining Available for                Future Issuance Under Equity Compensation Plans” consists of 2,173,667 shares available under the 2019 Omnibus Incentive Plan. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ITEM 15. | EXHIBITS, FINANCIAL STATEMENT SCHEDULES |
|----------|-----------------------------------------|
| (a) | The following is filed as part of the 2019 Form 10-K: |
|-----|-------------------------------------------------------|
|  | (1) | Index to Consolidated Financial Statements in Item 8 of 2019 Form 10-K. |
|--|-----|-------------------------------------------------------------------------|
| (b) | The following exhibits are included herein or incorporated herein by reference. |
|-----|---------------------------------------------------------------------------------|

| Exhibit No.  |   | Description                                                                                                                                                                                                                                                                                                     |
|--------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1          |   | Articles of Incorporation, as amended, of Chembio Diagnostics, Inc.                                                                                                                                                                                                                                             |
| 3.2          |   | Amended and Restated Bylaws, of Chembio Diagnostics, Inc.                                                                                                                                                                                                                                                       |
| 4.1          |   | Warrant to Purchase Common Stock dated as of September 3, 2019, issued by Chembio Diagnostics, Inc. to Perceptive                      Credit Holdings II, LP                                                                                                                                                   |
| 10.1(a)*     |   | 2008 Stock Incentive Plan, as amended                                                                                                                                                                                                                                                                           |
| 10.1(b)*     |   | Form of Option for 2008 Stock Incentive Plan                                                                                                                                                                                                                                                                    |
| 10.2(a)*     |   | 2014 Stock Incentive Plan                                                                                                                                                                                                                                                                                       |
| 10.2(b)*     |   | Form of Option for 2014 Stock Incentive Plan                                                                                                                                                                                                                                                                    |
| 10.3*        |   | 2019 Omnibus Incentive Plan                                                                                                                                                                                                                                                                                     |
| 10.4*        |   | Restated Annual Incentive Bonus Plan of Chembio Diagnostics, Inc., adopted as of March 15, 2019                                                                                                                                                                                                                 |
| 10.5*‡ |   | Employment Agreement, dated as of March 4, 2020 and effective                        as of March 16, 2020, between Chembio Diagnostics, Inc. and Richard L. Eberly                                                                                                                                              |
| 10.6*        |   | Letter agreement dated January 17, 2020, between Chembio Diagnostics, Inc. and Gail S. Page                                                                                                                                                                                                                     |
| 10.7(a)*     |   | Employment Agreement dated March 5, 2016 between Chembio Diagnostics, Inc. and Javan Esfandiari                                                                                                                                                                                                                 |
| 10.7(b)*     |   | Amendment No. 1 dated March 20, 2019 between Chembio Diagnostics, Inc. and Javan Esfandiari, amending the                      Employment Agreement dated March 5, 2016                                                                                                                                         |
| 10.8*        |   | Employment Agreement dated September 14, 2017 between Chembio Diagnostics, Inc. and Sharon Klugewicz                                                                                                                                                                                                            |
| 10.9(a)*     |   | Employment Agreement dated December 18, 2017 between Chembio Diagnostics, Inc. and Neil A. Goldman                                                                                                                                                                                                              |
| 10.9(b)*     |   | Amendment No. 1 dated January 21, 2019 between Chembio Diagnostics, Inc. and Neil A. Goldman, amending Employment                      Agreement dated December 18, 2017                                                                                                                                        |
| 10.10*       |   | Offer Letter dated October 19, 2016 between Worldwide Workplace Ireland and Robert Passas, with respect                      to employment by Chembio Diagnostics Systems, Inc.                                                                                                                                 |
| 10.11        |   | Separation and Release Agreement, dated January 7, 2020, between Chembio Diagnostics, Inc. and John J. Sperzel III                                                                                                                                                                                              |
| 10.12(a)     |   | Lease Agreement, dated February 15, 2017, between Horseblock Associates and Chembio Diagnostics, Inc.                      with respect to 3661 Horseblock Road, Medford, New York, as amended                                                                                                                  |
| 10.12(b)     |   | Agreement of Sublease dated February 5, 2019 between Chembio Diagnostic Systems Inc., as sublessor, and Reliance                      Communications of New Jersey, LLC, as sublessee, with respect to 3661 Horseblock Road, Medford, New York, as amended                                                      |
| 10.13        |   | Lease Agreement, dated February 4, 2013, between Sherwood Corporate Center LLC and Chembio Diagnostics,                      Inc. with respect to 91-1A Colin Drive, Holbrook, New York, as amended on September 19, 2017                                                                                       |
| 10.14        |   | Lease Agreement dated February 5, 2019 between Myra Properties, LLC, as lessor, and Chembio Diagnostic Systems                      Inc., as lessee, with respect to 555 Wireless Boulevard, Hauppauge, New York.                                                                                               |
| 10.15† |   | Credit Agreement and Guaranty dated as of September 3, 2019, among Chembio Diagnostics, Inc., as the Borrower, the                      Guarantors from time to time party thereto, and Perceptive Credit Holdings II, LP and its successors and assigns party thereto, as Administrative Agent and as a Lender |
| 14.1         |   | Ethics Policy                                                                                                                                                                                                                                                                                                   |
| 21.1         |   | List of Subsidiaries of Chembio Diagnostics, Inc.                                                                                                                                                                                                                                                               |
| 23.1         |   | Consent of BDO USA, LLP, Independent Registered Public Accounting Firm                                                                                                                                                                                                                                          |

----

Table of Contents

| 31.1       |   | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                                         |
|------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 31.2       |   | Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                                         |
| 32.1ç |   | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as                    adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS    |   | XBRL Instance Document                                                                                                                                                                          |
| 101.SCH    |   | XBRL Taxonomy Extension Schema Document                                                                                                                                                         |
| 101.CAL    |   | XBRL Taxonomy Extension Calculation Linkbase Document                                                                                                                                           |
| 101.DEF    |   | XBRL Taxonomy Definition Linkbase Document                                                                                                                                                      |
| 101.LAB    |   | XBRL Taxonomy Label Linkbase Document                                                                                                                                                           |
| 101.PRE    |   | XBRL Taxonomy Presentation Linkbase Document                                                                                                                                                    |

| * | Indicates management contract or compensatory plan. |
|---|-----------------------------------------------------|

| † | Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of omitted exhibits and schedules upon request by the Securities                and Exchange Commission, provided that it may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934 for exhibits and schedules so furnished. |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ‡ | Certain sensitive personally identifiable information in this exhibit was omitted by means of redacting a portion of the text and replacing it with [***]. |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ç | The certifications attached as Exhibit 32.1 accompany the Annual Report on Form 10-K pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be                deemed “filed” by the registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|                     | CHEMBIO DIAGNOSTICS, INC. |
|--------------------------|---------------------------|
|                     |                      |   |
| Dated:  May 6, 2020 | By:                       | /s/ Neil A. Goldman |
|                     |                      | Name: Neil A. Goldman |
|                     |                      | Title: Executive Vice President and Chief Financial Officer |

----